PBC is an autoimmune liver disease in which the bile ducts are damaged or destroyed, causing impaired bile flow. This exposes the liver to higher than normal levels of bile acids, causing damage over time that may lead to cirrhosis and liver failure. PBC is primarily a disease of women, impacting approximately one in 1,000 women over the age of 40.1 It is the second leading indication for liver transplant among women in the United States.2
Studies estimate that approximately 40% of patients do not achieve an adequate response to therapy,3-7 leaving them at greater risk of adverse outcomes.
WHAT: Results from Phase 3 and Phase 2 trials of an investigational therapy known as obeticholic acid (OCA) will be presented at Digestive Disease Week, the largest international conference for healthcare professionals working in the fields of gastroenterology and hepatology.
In addition to PBC, OCA is also under investigation as a treatment for other chronic liver diseases, including nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
WHO: Kris V. Kowdley, MD, FACP, FACG, AGAF, Director of the Liver Care Network at Swedish Medical Center and Clinical Professor of Medicine at the University of Washington, will be presenting the study results in an oral session at DDW. Dr. Kowdley has presented his research in liver diseases at more than 135 national and international medical centers and scientific symposia and his research has been published in the New England Journal of Medicine, Annals of Internal Medicine, Gastroenterology and Hepatology, among other professional publications.
WHEN: The presentation at DDW takes place on Monday, May 18, 2015 from 3:15 PM to 3:30 PM at the Walter E. Washington Convention Center, Washington, DC. Room 208.
WHY: This is an exciting time for the practice of hepatology, as healthcare professionals turn their attention from the major strides made in the treatment of Hepatitis C to liver disease like PBC and NASH that have limited therapeutic options.
HOW: For more information contact Glenn Silver at (646) 871-8485 or gsilver@lazarpartners.com.
Help employers find you! Check out all the jobs and post your resume.
Studies estimate that approximately 40% of patients do not achieve an adequate response to therapy,3-7 leaving them at greater risk of adverse outcomes.
WHAT: Results from Phase 3 and Phase 2 trials of an investigational therapy known as obeticholic acid (OCA) will be presented at Digestive Disease Week, the largest international conference for healthcare professionals working in the fields of gastroenterology and hepatology.
In addition to PBC, OCA is also under investigation as a treatment for other chronic liver diseases, including nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
WHO: Kris V. Kowdley, MD, FACP, FACG, AGAF, Director of the Liver Care Network at Swedish Medical Center and Clinical Professor of Medicine at the University of Washington, will be presenting the study results in an oral session at DDW. Dr. Kowdley has presented his research in liver diseases at more than 135 national and international medical centers and scientific symposia and his research has been published in the New England Journal of Medicine, Annals of Internal Medicine, Gastroenterology and Hepatology, among other professional publications.
WHEN: The presentation at DDW takes place on Monday, May 18, 2015 from 3:15 PM to 3:30 PM at the Walter E. Washington Convention Center, Washington, DC. Room 208.
WHY: This is an exciting time for the practice of hepatology, as healthcare professionals turn their attention from the major strides made in the treatment of Hepatitis C to liver disease like PBC and NASH that have limited therapeutic options.
HOW: For more information contact Glenn Silver at (646) 871-8485 or gsilver@lazarpartners.com.
Help employers find you! Check out all the jobs and post your resume.
